SIMPONI is designed to treat moderately to severely active UC in patients who have not responded well to past conventional therapies. It is the first and only subcutaneous anti-tumor necrosis factor alpha treatment administered every four weeks for UC therapy.
More Articles on Gastroenterology:
GlaxoSmithKline Returns Drug Rights to ChemoCentryx After Failed Trial
5 Recent GI Center Openings, Plans & Expansions
“S” or “C” Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
